// AST – IMS - [DMinute_ROS]

Speece Thorson Capital Group Cut Its Position in C H Robinson Worldwide (CHRW) by $5.23 Million; As Achillion Pharmaceuticals (ACHN) Stock Rose, Ecor1 Capital Lifted Stake

C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW) Logo

Speece Thorson Capital Group Inc decreased its stake in C H Robinson Worldwide Inc (CHRW) by 44.39% based on its latest 2018Q2 regulatory filing with the SEC. Speece Thorson Capital Group Inc sold 63,041 shares as the company’s stock rose 9.16% with the market. The hedge fund held 78,960 shares of the transportation company at the end of 2018Q2, valued at $6.61M, down from 142,001 at the end of the previous reported quarter. Speece Thorson Capital Group Inc who had been investing in C H Robinson Worldwide Inc for a number of months, seems to be less bullish one the $12.14B market cap company. The stock decreased 0.66% or $0.59 during the last trading session, reaching $88.28. About 73,663 shares traded. C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW) has risen 36.16% since December 6, 2017 and is uptrending. It has outperformed by 20.54% the S&P500. Some Historical CHRW News: 10/05/2018 – C.H. ROBINSON BOOSTS SHARE BUYBACK AUTHORIZATION; 01/05/2018 – CH Robinson Worldwide 1Q EPS $1.01; 09/04/2018 – C.H. ROBINSON WORLDWIDE INC FILES PRELIMINARY PROSPECTUS SUPPLEMENT RELATED TO A POTENTIAL NOTES OFFERING – SEC FILING; 16/04/2018 – C.H. ROBINSON WORLDWIDE INC CHRW.O : UBS RAISES TARGET PRICE TO $110 FROM $97; 08/05/2018 – C.H. Robinson Launches Rail Service, Connecting China and Europe; 26/04/2018 – C.H. Robinson Closes Below 50-Day Moving Average: Technicals; 01/05/2018 – CH Robinson Worldwide 1Q Rev $3.93B; 01/05/2018 – C.H. ROBINSON 1Q EPS $1.01; 06/03/2018 Glancy Prongay & Murray LLP Commences Investigation on Behalf of C.H. Robinson Worldwide, Inc. (CHRW) Investors; 08/05/2018 – C.H. Robinson to Participate in the Bank of America Merrill Lynch 2018 Transportation and the 2018 Wolfe Research Global Transportation Conferences

Ecor1 Capital Llc increased its stake in Achillion Pharmaceuticals Inc (ACHN) by 5.97% based on its latest 2018Q2 regulatory filing with the SEC. Ecor1 Capital Llc bought 219,100 shares as the company’s stock rose 10.74% with the market. The institutional investor held 3.89 million shares of the health care company at the end of 2018Q2, valued at $11.00M, up from 3.67M at the end of the previous reported quarter. Ecor1 Capital Llc who had been investing in Achillion Pharmaceuticals Inc for a number of months, seems to be bullish on the $420.01 million market cap company. The stock increased 0.66% or $0.02 during the last trading session, reaching $3.03. About 67,359 shares traded. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has declined 11.53% since December 6, 2017 and is downtrending. It has underperformed by 27.15% the S&P500. Some Historical ACHN News: 18/05/2018 – Achillion Closes Above 200-Day Moving Average: Technicals; 11/05/2018 – Achillion Announces Upcoming Scientific Presentations at the 55th ERA-EDTA Congress; 15/05/2018 – Orbimed Advisors LLC Exits Position in Achillion; 02/05/2018 – Achillion Pharmaceuticals 1Q Loss/Shr 15c; 02/05/2018 – ACHILLION SAYS JOSEPH TRUITT NAMED CEO; 09/05/2018 – Achillion Short-Interest Ratio Rises 53% to 12 Days; 15/05/2018 – Armistice Capital Buys New 3.1% Position in Achillion; 07/05/2018 – Achillion at Deutsche Bank Health Care Conference Tomorrow; 02/05/2018 – Achillion Pharmaceuticals Appoints Joseph Truitt CEO; 15/05/2018 – Sarissa Adds Shire, Cuts Achillion: 13F

Investors sentiment increased to 1.38 in Q2 2018. Its up 0.43, from 0.95 in 2018Q1. It improved, as 11 investors sold ACHN shares while 29 reduced holdings. 16 funds opened positions while 39 raised stakes. 105.68 million shares or 1.67% less from 107.48 million shares in 2018Q1 were reported. Tiaa Cref Inv Ltd Liability Company holds 621,860 shares or 0% of its portfolio. Nj State Employees Deferred Compensation Plan accumulated 30,000 shares or 0.02% of the stock. New York-based D E Shaw has invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Credit Suisse Ag invested in 197,605 shares. 56,237 were accumulated by Bluemountain Capital Management Ltd Liability Co. Creative Planning reported 0% stake. Great Point Ltd owns 2.99M shares for 1.17% of their portfolio. Illinois-based Balyasny Asset Management Limited Liability Co has invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). South Dakota Inv Council invested 0.05% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Panagora Asset Management stated it has 0.01% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Deutsche National Bank Ag has 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 1.96M shares. Armistice Capital Ltd Liability Co stated it has 4.00 million shares. Ameriprise has 59,210 shares for 0% of their portfolio. Perceptive Advisors Lc invested in 0.07% or 1.00 million shares. Renaissance Tech Lc reported 875,899 shares.

Among 12 analysts covering Achillion Pharma (NASDAQ:ACHN), 6 have Buy rating, 0 Sell and 6 Hold. Therefore 50% are positive. Achillion Pharma had 28 analyst reports since August 13, 2015 according to SRatingsIntel. The firm has “Market Outperform” rating given on Thursday, July 7 by JMP Securities. FBR Capital initiated the shares of ACHN in report on Wednesday, February 7 with “Hold” rating. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has “Sell” rating given on Thursday, July 14 by Chardan Capital Markets. The firm has “Buy” rating by Maxim Group given on Thursday, August 13. The rating was maintained by Chardan Capital Markets on Friday, September 23 with “Sell”. On Thursday, August 10 the stock rating was downgraded by Robert W. Baird to “Neutral”. The rating was initiated by Wedbush on Friday, September 23 with “Outperform”. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) earned “Hold” rating by Chardan Capital Markets on Wednesday, August 9. Ladenburg Thalmann initiated the stock with “Buy” rating in Thursday, February 2 report. As per Friday, February 26, the company rating was upgraded by Robert W. Baird.

More notable recent Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) news were published by: Globenewswire.com which released: “Achillion to Present at the Baird 2018 Global Healthcare Conference – GlobeNewswire” on August 30, 2018, also Globenewswire.com with their article: “Achillion Expands Management Team With Appointment of Anthony S. Gibney as Chief Business Officer – GlobeNewswire” published on August 15, 2018, Seekingalpha.com published: “Achillion Pharmaceuticals: Overlooked Value Play Or Potential Trap? – Seeking Alpha” on November 28, 2018. More interesting news about Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) were released by: Globenewswire.com and their article: “Achillion Appoints Dr. Steven Zelenkofske as Chief Medical Officer and Further Strengthens Clinical Development Team – GlobeNewswire” published on August 21, 2018 as well as Globenewswire.com‘s news article titled: “Achillion Appoints Paul Firuta Chief Operating Officer – GlobeNewswire” with publication date: September 10, 2018.

Speece Thorson Capital Group Inc, which manages about $408.00M and $474.55M US Long portfolio, upped its stake in Valmont Inds Inc (NYSE:VMI) by 8,299 shares to 80,927 shares, valued at $12.20 million in 2018Q2, according to the filing. It also increased its holding in Devon Energy Corp New (NYSE:DVN) by 61,612 shares in the quarter, for a total of 398,983 shares, and has risen its stake in Eaton Corp Plc Shs (NYSE:ETN).

Among 25 analysts covering C.H. Robinson Worldwide (NASDAQ:CHRW), 12 have Buy rating, 2 Sell and 11 Hold. Therefore 48% are positive. C.H. Robinson Worldwide had 104 analyst reports since July 30, 2015 according to SRatingsIntel. The company was downgraded on Thursday, August 20 by Zacks. The firm earned “Buy” rating on Wednesday, August 1 by Bank of America. Susquehanna maintained C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW) rating on Thursday, October 29. Susquehanna has “Neutral” rating and $76 target. Stephens downgraded C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW) rating on Thursday, April 28. Stephens has “Equal-Weight” rating and $76 target. The stock of C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW) earned “Outperform” rating by Cowen & Co on Monday, October 16. BB&T Capital upgraded the shares of CHRW in report on Monday, September 28 to “Buy” rating. UBS upgraded C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW) on Thursday, January 7 to “Neutral” rating. The stock of C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW) has “Hold” rating given on Thursday, October 5 by Robert W. Baird. Cowen & Co maintained C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW) on Wednesday, July 29 with “Market Perform” rating. Evercore initiated it with “Buy” rating and $81 target in Wednesday, August 19 report.

More notable recent C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW) news were published by: Nasdaq.com which released: “Expeditors International of Washington, Inc. (EXPD) Ex-Dividend Date Scheduled for November 30, 2018 – Nasdaq” on November 29, 2018, also Nasdaq.com with their article: “Forward Air Corporation (FWRD) Ex-Dividend Date Scheduled for November 21, 2018 – Nasdaq” published on November 20, 2018, Nasdaq.com published: “Macquarie Infrastructure Corporation (MIC) Ex-Dividend Date Scheduled for November 08, 2018 – Nasdaq” on November 07, 2018. More interesting news about C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW) were released by: Nasdaq.com and their article: “C.H. Robinson (CHRW) Up 3.2% Since Last Earnings Report: Can It Continue? – Nasdaq” published on November 29, 2018 as well as Nasdaq.com‘s news article titled: “Why C.H. Robinson (CHRW) is Such a Great Value Stock Pick Right Now – Nasdaq” with publication date: November 23, 2018.

C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.